$0.7884
-0.0818-9.4%
Perspective Therapeutics Inc
CATXAMEX
The average analyst price target for Perspective Therapeutics is $12.19. Of 15 analysts, 13 rate it Buy and 2 Hold. Targets range from $4 to $22. The latest change came on Oct 26, 2026, when RBC Capital downgraded Perspective Therapeutics from Outperform to Sector Perform and moved its price target from $14 to $4.
Price Target Range — 13 Quarters
Analyst Consensus — 15 Analysts
Rating Trend — Last 9 Months
